Stock SYNTA PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. Synta Pharmaceuticals Corp. Nasdaq

Equities

US87162T2069

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Synta Pharmaceuticals Corp.
Apr. 11 Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Apr. 11 Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing
MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating
MT
Madrigal commences $500 million public offering of common stock
RE
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating
MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating
MT
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating
MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating
MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating
MT
B. Riley Upgrades Madrigal Pharmaceuticals to Neutral From Sell After FDA Approval of Rezdiffra, Raises PT to $270 From $155
MT
HC Wainwright Adjusts Madrigal Pharmaceuticals' Price Target to $405 From $275, Maintains Buy Rating
MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $320 From $300, Maintains Outperform Rating
MT
B. Riley Downgrades Madrigal Pharmaceuticals to Sell From Neutral, Says Nearly All Stock Scenarios Point to Higher Likelihood of Downside; Adjusts PT to $155 From $204
MT
B. Riley Downgrades Madrigal Pharmaceuticals to Sell From Neutral, Cuts Price Target to $155 From $204
MT
Piper Sandler Adjusts Price Target on Madrigal Pharmaceuticals to $336 From $305, Maintains Overweight Rating
MT
Jefferies Cuts Madrigal Pharmaceuticals Price Target to $321 From $340, Maintains Buy Rating
MT
B. Riley Raises Madrigal Pharmaceuticals' PT to $204 From $154 on Increased Resmetirom Pricing Guidance, Keeps Neutral Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. Stock
  5. News Synta Pharmaceuticals Corp.
  6. Analyst Reco.